A Biomarker Bakeoff in Early Stage Pancreatic Cancer
- Abbreviated Name
- PaCa Bake Off 1
- Lead Investigator
- Brand, Randall E. — University of Pittsburgh
- Coordinating Investigator
- Feng, Ziding — Fred Hutchinson Cancer Center
- Involved Investigators
-
- Feng, Ziding — Fred Hutchinson Cancer Center
- Lokshin, Anna — University of Pittsburgh Cancer Institute
- Batra, Surinder — University of Nebraska Medical Center
- Lampe, Paul — Fred Hutchinson Cancer Center
- Haab, Brian — Van Andel Research Institute
- Brand, Randall E. — University of Pittsburgh
- Hanash, Samir — The University of Texas MD Anderson Cancer Center
- Maitra, Anirban — The University of Texas M D Anderson Cancer Center
Abstact
The gastrointestinal collaborative group within the EDRN is in an optimal position to carry out such a study given its shared resources and interactive structure. In this project, the two pancreatic CVCs in the EDRN will provide samples to be distributed to four laboratories with promising biomarkers. The laboratories will run their own assays and perform initial analyses on the blinded PDAC and control samples. Our biostatistical collaborator, Dr. Huang at FHCRC, will perform the statistical evaluations. Biomarkers meeting the predetermined performance criteria will move forward to further validation using the EDRN reference set. In addition, we will determine whether any novel combinations of biomarkers should be further tested.
Aims
Specific Aim 1: Compare the performance of several candidate biomarkers for discriminating resectable PDAC from benign pancreatic disease both alone and in combination with CA19. Specific Aim 2: Test the value of novel combinations of biomarkers to identify candidates for further testing using the reference set.
Analytic Method
Once the composition of the sample set is finalized by the two CVCs, aliquots of the samples will be transferred to each of the four laboratories running the biomarker experiments. Each site will run its own biomarker assays and perform initial data processing. Based on rules that will be predetermined, each site will make classifications of each sample as a case or control. The calls and data will be sent to Dr. Huang at FHCRC. Dr. Huang will have access to the diagnoses associated with the samples, from which she will determine the performance of the candidate biomarkers and make statistical comparisons among them and CA19-9. CA19-9 measurements will be provided by the laboratories of Drs. Haab and Batra. Information on each of the candidate biomarkers is provided in the following sections.
Publications
- No publications available at this time for this protocol.
Biomarkers
Data Collections
- No data collections available at this time for this protocol.
Team Project
- Start Date
- May 1 2017
- Estimated Finish Date
- Apr 30 2018
- Protocol ID
- 421
- Protocol Type
- Collaboration
- Field of Research
- Proteomics
- Collaborative Group
- G.I. and Other Associated Cancers Research Group
- Cancer Types
-
- Malignant neoplasm of pancreas
- Phased Status
- 1